Advertisement Pharmaceutical Business review - Page 810 of 5273 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
May 18, 2026

FDA approves Enhertu for two HER2-positive early breast cancer indications

The US Food and Drug Administration (FDA) has approved Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) for two new indications in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer.

In the neoadjuvant setting, the therapy is approved for adults with HER2-positive stage 2 or stage 3 breast cancer. Credit: Arif biswas / Shutterstock.com.